Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 4.155 EUR 2.09% Market Closed
Market Cap: 195.8m EUR

EV/EBITDA
Enterprise Value to EBITDA

-2.9
Current
-2.9
Median
4.4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-2.9
=
Enterprise Value
191.9m EUR
/
EBITDA
-66.8m EUR
EBITDA Growth EV/EBITDA to Growth
FR
Nanobiotix SA
PAR:NANO
Average EV/EBITDA: 15.4
Negative Multiple: -2.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 789.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.5
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -650.3 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-4.5
2-Years Forward
EV/EBITDA
10.1
3-Years Forward
EV/EBITDA
13.7